This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Neurology  • Stroke  • Treatment Adherence  • Randomized Controlled Trial  • Prognosis/ Outcomes  • Arrhythmias  • Cardiovascular Disease/ Myocardial Infarction  • Adherence  • Alert me on articles by topic

Results From SPORTIF III and V

Harvey D. White, DSc; Michael Gruber, MSc; Jan Feyzi, MS; Scott Kaatz, DO; Hung-Fat Tse, MD; Steen Husted, MD; Gregory W. Albers, MD

Arch Intern Med. 2007;167(3):239-245.

Background  Warfarin sodium reduces stroke risk in patients with atrial fibrillation, but international normalized ratio (INR) monitoring is required. Target INRs are frequently not achieved, and the risk of death, bleeding, myocardial infarction (MI), and stroke or systemic embolism event (SEE) may be related to INR control.

Methods  We analyzed the relationship between INR control and the rates of death, bleeding, MI, and stroke or SEE among 3587 patients with atrial fibrillation randomized to receive warfarin treatment in the SPORTIF (Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation) III and V trials. The mean±SD follow-up was 16.6 ± 6.3 months. Patients were divided into 3 equal groups (those with good control [>75%], those with moderate control [60%-75%], or those with poor control [<60%]) according to the percentage time with an INR of 2.0 to 3.0. Outcomes were compared according to INR control. The main outcome measures were death, bleeding, MI, and stroke or SEE.

Results  The poor control group had higher rates of annual mortality (4.20%) and major bleeding (3.85%) compared with the moderate control group (1.84% and 1.96%, respectively) and the good control group (1.69% and 1.58%, respectively) (P<.01 for all). Compared with the good control group, the poor control group had higher rates of MI (1.38% vs 0.62%, P = .04) and of stroke or SEE (2.10% vs 1.07%, P = .02).

Conclusions  In patients with atrial fibrillation taking warfarin, the risks of death, MI, major bleeding, and stroke or SEE are related to INR control. Good INR control is important to improve patient outcomes.

Author Affiliations: Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand (Dr White); Department of Biostatistics, University of Wisconsin–Madison (Mr Gruber and Ms Feyzi); Department of Internal Medicine, Henry Ford Hospital, Detroit, Mich (Dr Kaatz); Cardiology Division, Department of Medicine, Queen Mary Hospital, Hong Kong (Dr Tse); Department of Medicine and Cardiology, Aarhus University Hospital, Aarhus, Denmark (Dr Husted); and Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, Calif (Dr Albers).

RELATED ARTICLES

The Influence of Patient Adherence on Anticoagulation Control With Warfarin: Results From the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study
Stephen E. Kimmel, Zhen Chen, Maureen Price, Catherine S. Parker, Joshua P. Metlay, Jason D. Christie, Colleen M. Brensinger, Craig W. Newcomb, Frederick F. Samaha, and Robert Gross
Arch Intern Med. 2007;167(3):229-235.
ABSTRACT | FULL TEXT  

Newly Detected Atrial Fibrillation and Compliance With Antithrombotic Guidelines
Nicole L. Glazer, Sascha Dublin, Nicholas L. Smith, Benjamin French, Lisa A. Jackson, Jennifer B. Hrachovec, David S. Siscovick, Bruce M. Psaty, and Susan R. Heckbert
Arch Intern Med. 2007;167(3):246-252.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
Connolly et al.
Circulation 2008;118:2029-2037.
ABSTRACT | FULL TEXT  

Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation: Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V
Hylek et al.
Stroke 2008;39:3009-3014.
ABSTRACT | FULL TEXT  

Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Ansell et al.
Chest 2008;133:160S-198S.
ABSTRACT | FULL TEXT  

An update on cardioembolic stroke
Weir
Postgrad. Med. J. 2008;84:133-142.
ABSTRACT | FULL TEXT  

Warfarin Therapy in Clinical Practice
JWatch Neurology 2007;2007:2-2.
FULL TEXT  

Evidently...
Lehmann
Evid. Based Med. 2007;12:69-69.
FULL TEXT  

Other articles noted
Evid. Based Med. 2007;12:95-96.
FULL TEXT